Early detection and intervention are crucial to reducing the burden of DKD [9,10], especially given that, in addition to conventional measures including optimised blood glucose/blood pressure control and renin–angiotensin system blockade [11,12,13], newer pharmacotherapies, specifically the sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and mineralocorticoid receptor antagonists, have been shown to reduce DKD progression [14]. The gene discussed is SLC5A2; the disease is diabetic kidney disease.